Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)

被引：3
|
作者：
Piratvisuth, T.
Lau, G. K. K.
Marcellin, P.
Chow, W. C.
Cooksley, G.
Fried, M. W.
Paik, S. W.
Liaw, Y. F.
Popescu, M.
Button, P.
机构：
[1] Prince Songkla Univ, Dept Internal Med, Songklanagarind Hosp, Hat Yai, Thailand
[2] Univ Hong Kong, Queen Marys Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Hop Beaujon, Serv Hepatol, Clichy, France
[4] Singapore Gen Hosp, Dept Gastroenterol, Singapore 0316, Singapore
[5] Royal Brisbane Hosp, Dept Clin Res, Brisbane, Qld 4029, Australia
[6] Univ N Carolina, Univ N Carolina Liver Program, Chapel Hill, NC USA
[7] Samsung Med Ctr, Dept Gastroenterol, Seoul, South Korea
[8] Chang Gung Mem Hosp, Linkou, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2006年 / 44卷
关键词：
D O I：
10.1016/S0168-8278(06)80050-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
49
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [1] HBeAg and HBV DNA kinetics in HBsAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB)
    Fried, M. W.
    Liaw, Y. F.
    Luo, K. X.
    Lau, G. K. K.
    Piratvisuth, T.
    Cooksley, G.
    Marcellin, P.
    Flisiak, R.
    Popescu, M.
    Button, P.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S183 - S183
  • [2] Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-POSITIVE or HBeAg-negative chronic hepatitis B (CHB)
    Cooksley, G.
    Lau, G. K. K.
    Marcellin, P.
    Piratvisuth, T.
    Bonino, F.
    Luo, K. X.
    Hadziyannis, S.
    Jin, R.
    Button, P.
    Pluck, N.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S182 - S183
  • [3] Characterization of Hepatitis B Surface Proteins in HBeAg-positive Patients with Chronic Hepatitis B (CHB) Treated With PegInterferon Alfa-2a (40KD)
    Rinker, Franziska
    Bremer, Corinna M.
    Wiegand, Steffen B.
    Bremer, Birgit
    Manns, Michael P.
    Wedemeyer, Heiner
    Yang, Lei
    Pavlovic, Vedran
    Wat, Cynthia
    Glebe, Dieter
    Kraft, Anke R.
    Cornberg, Markus
    [J]. HEPATOLOGY, 2015, 62 : 1196A - 1197A
  • [4] Predictors of histologic improvement and relationship between sustained response and histology in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®)
    Lau, GK
    Cooksley, G
    Marcellin, P
    Piratvisuth, T
    Hadziyannis, S
    Farci, P
    Fried, MW
    Bonino, F
    Jin, R
    Button, P
    Popescu, M
    [J]. HEPATOLOGY, 2005, 42 (04) : 587A - 587A
  • [5] HBV DNA Suppression in HBeAg-Positive Chronic Hepatitis B Patients Treated With Peginterferon or Placebo
    Hansen, Bettina E.
    Rijckborst, Vincent
    ter Borg, Martijn J.
    Janssen, Harry L. A.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (11) : 1917 - 1923
  • [6] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [7] Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B
    Lau, G. K. K.
    Piratvisuth, T.
    Luo, K. X.
    Marcellin, P.
    Thongsawat, S.
    Cooksley, G.
    Gane, E.
    Fried, M. W.
    Popescu, M.
    Wu, J.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S23 - S24
  • [8] SERUM HBVRNA IS AN EARLY PREDICTOR OF HBeAg SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH PEG-INTERFERON ALPHA-2A (40kD)
    van Boemmel, F.
    van Boemmel, A.
    Krauel, A.
    He, H.
    Wat, C.
    Pavlovic, V.
    Deichsel, D.
    Berg, T.
    Boehm, S.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S560 - S561
  • [9] Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®]
    Marcellin, P.
    Bonino, F.
    Lau, G. K. K.
    Farci, P.
    Yurdaydin, C.
    Piratvisuth, T.
    Jin, R.
    Gurel, S.
    Hadziyannis, S.
    Lu, Z.
    Popescu, M.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S95 - S96
  • [10] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
    Caruntu, Florin Alexandru
    Streinu-Cercel, Adrian
    Gheorghe, Liliana Simona
    Grigorescu, Mircea
    Sporea, Ioan
    Stanciu, Carol
    Andronescu, Dan
    Voinea, Florea
    Diculescu, Mircea
    Oproiu, Alexandru
    Voiosu, Rodu
    [J]. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
12345